PT-141 (Bremelanotide) Dosage Guide
Complete guide to PT-141 (Bremelanotide) dosing protocols, administration methods, and safety considerations for research purposes.
Dosage Overview
Dose per Injection
1.8 mg
Frequency
Once per week
Route
subcutaneous
Cycle Length
4–12 weeks
Reconstitution
Vial Size
10 mg
BAC Water
2.0 ml
Concentration
5,000 mcg/ml
Detailed Dosage Information
FDA-approved dose
1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity.
Not to be used more than once within 24 hours or more than 8 times per month.
Administration Method
Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols.
Research Use Only: All dosage ranges and calculations are derived from published research literature and are provided for educational purposes. These are not prescriptions or medical recommendations. Consult a healthcare professional before any use.
Concentration: 5 mg/ml
Volume to inject: 0.350 ml
Syringe units: 35.0 units — fits 0.5 ml syringe
U-100 insulin syringe (100 units = 1 ml). Verify dose with a clinician before injecting.
Pre-filled with PT-141 (Bremelanotide) defaults. Adjust values as needed.
Side Effects to Monitor
Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur.
Safety Considerations & Risks
Not recommended for use with alcohol. May cause significant nausea. Should not be used in patients with uncontrolled hypertension or cardiovascular disease.